# chronic TED FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-ted

> 1 upcoming FDA catalyst in chronic TED: elegrobart (VRDN) on Q1 2027 (NDA/BLA submission).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for chronic TED?

1 upcoming FDA catalyst in chronic TED: elegrobart (VRDN) on Q1 2027 (NDA/BLA submission). Press release filed with the SEC (EX-99): "Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/indications/chronic-ted)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-446200, https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/indications/chronic-ted#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 16, 2024 | [Lumvoa™ (veligrotug) topline data readout](https://sec-api.dev/pdufa/veligrotug) | VRDN | chronic TED | completed, positive | "WALTHAM, Mass., December 16, 2024  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312524279021/d648282dex991.htm)) |
| Q2 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN | chronic TED | scheduled | "- REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex991.htm)) |
| Q1 2027 | [Elegrobart NDA/BLA submission](https://sec-api.dev/pdufa/elegrobart) | VRDN | chronic TED | scheduled | "Our pipeline also continues to move forward as we advance elegrobart, our subcutaneously administered anti-IGF-1R, toward a planned BLA submission for TED in the first quarter of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526446200/d176865dex991.htm)) |

## Drugs

- [Lumvoa™ (veligrotug)](https://sec-api.dev/pdufa/veligrotug) (VRDN)
- [Elegrobart](https://sec-api.dev/pdufa/elegrobart) (VRDN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-ted.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "chronic TED FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-ted

```bibtex
@misc{secapidev_indications_chronic_ted_20261116,
  title        = {chronic TED FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-ted}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_ted_20261116","title":"chronic TED FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-ted","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
